HCW Biologics Inc (HCWB) - Total Liabilities
Based on the latest financial reports, HCW Biologics Inc (HCWB) has total liabilities worth $21.76 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
HCW Biologics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how HCW Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. See HCW Biologics Inc (HCWB) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
HCW Biologics Inc Competitors by Total Liabilities
The table below lists competitors of HCW Biologics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AGM Group Holdings Inc Class A
NASDAQ:AGMH
|
USA | $28.66 Million |
|
CrownHaitai Holdings Co Ltd Preference Shares
KO:005745
|
Korea | ₩584.83 Billion |
|
Magle Chemoswed Holding Ab
ST:MAGLE
|
Sweden | Skr515.19 Million |
|
Ace Integrated Solutions Limited
NSE:ACEINTEG
|
India | Rs3.00 Million |
|
TECIL Chemicals and Hydro Power Limited
NSE:TECILCHEM
|
India | Rs228.60 Million |
|
Accsys Technologies PLC
LSE:AXS
|
UK | GBX89.24 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down HCW Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HCWB market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 7.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.89 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HCW Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HCW Biologics Inc (2019–2025)
The table below shows the annual total liabilities of HCW Biologics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $21.76 Million | -41.21% |
| 2024-12-31 | $37.01 Million | +145.86% |
| 2023-12-31 | $15.05 Million | +60.46% |
| 2022-12-31 | $9.38 Million | +304.06% |
| 2021-12-31 | $2.32 Million | +131.91% |
| 2020-12-31 | $1.00 Million | -6.10% |
| 2019-12-31 | $1.07 Million | -- |
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and … Read more